
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort Following Successful Initial Results Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing…












